Cytochrome P450 inhibitory potential of selected Indian spices ?possible food drug interaction
详细信息 查看全文
- 作者：Subrata Pandit ; Pulok K. Mukherjee<sup> ; sup><sup>naturalproductm@gmail.comsup> ; Kakali Mukherjee ; Rahul Gajbhiye ; M. Venkatesh ; S. Ponnusankar ; Santanu Bhadra
- 关键词：Indian spices ; Cytochrome P450 ; Standardization ; CYP3A4 ; CYP2D6 ; CYP2C9 ; CYP1A2 ; Food&ndash ; drug interaction
- 刊名：Food Research International
- 出版年：2012
- 出版时间：January 2012
- 年：2012
- 卷：45
- 期：1
- 页码：69-74
- 全文大小：874 K
文摘
Spices constitute an important group of food which is virtually indispensable in the culinary art. In a view, these spices feared to pose a probability to affect the disposition of conventional pharmaceuticals through inhibition of human cytochrome P450 (CYPs) enzymes. In the present study an approach has been made to evaluate the possible CYP inhibition potential with some Indian spices (Capsicum annuum, Murraya koenigii, Zingiber officinale) and their major bioactive compounds, in combination with pooled microsome; as well as commercially available recombinant human CYP3A4, CYP2D6, CYP2C9 and CYP1A2. Quantification of the bioactive compound was determined through RP-HPLC, in order to standardize the plant material. CYP-carbon monoxide (CYP-CO) complex assay result indicated that all the plants and their bioactive compounds have an interaction potential with CYPs. Fluoregenic assay results indicated that the spice extracts have higher inhibition potential comparing to their single bioactive molecule. The higher enzyme inhibition potential by the extracts may be related to the synergistic effects due to the presence of other constituents in the extract. Capsaicin and C. annuum showed the lowest IC<sub>50sub> value and 6-gingerol and Z. officinale extract showed the highest IC<sub>50sub> value among the entire sample tested. The entire sample showed significantly less (P < 0.001, P < 0.01) interaction potential than known inhibitors. These findings indicate that selected spices are unlikely to cause clinically relevant drug interactions involving the inhibition of major CYP isozymes.